Diaz Maureen H, Hersh Adam L, Olson Jared, Shah Samir S, Hall Matt, Edens Chris
MMWR Morb Mortal Wkly Rep. 2025 Jun 26;74(23):394-400. doi: 10.15585/mmwr.mm7423a1.
Mycoplasma pneumoniae is a common bacterial cause of respiratory infection and a leading cause of childhood community-acquired pneumonia (CAP). Increases in M. pneumoniae infection occur every 3-5 years. In the United States, M. pneumoniae prevalence decreased during and immediately after the COVID-19 pandemic. Information from 42 U.S. children's hospitals that provided information to the Pediatric Health Information System, a database of clinical and resource use information, was used to identify discharge diagnostic codes for 2018-2024 indicating M. pneumoniae infection. M. pneumoniae-associated CAP incidence among children aged ≤18 years was significantly higher in 2024 (12.5 per 1,000 hospitalizations) than during 2018-2023 (2.1). During the study period, an M. pneumoniae diagnostic code was listed in 11.5% of pediatric CAP hospitalizations, peaking at 53.8% in July 2024. Among pediatric M. pneumoniae CAP cases, the highest percentage occurred among children aged 6-12 years (42.6%), followed by children aged 2-5 years (25.7%) and 13-18 years (21.1%). The lowest occurred among those aged 12-23 months (6.4%) and 0-11 months (4.2%). M. pneumoniae infections in 2024 were not more severe than 2018-2023 infections, as assessed by length of hospitalization and percentage of patients admitted to an intensive care unit. The increase in M. pneumoniae infections in the United States in 2024 might be higher than previous periodic increases because the susceptible population was larger after sustained low incidence during and immediately after the COVID-19 pandemic. Health care providers should be aware of the periodicity of M. pneumoniae CAP and consider testing for this pathogen as a cause of respiratory illness among children of all ages.
肺炎支原体是呼吸道感染常见的细菌病因,也是儿童社区获得性肺炎(CAP)的主要病因。肺炎支原体感染每3至5年出现一次增加。在美国,肺炎支原体感染率在新冠疫情期间及之后立即下降。来自42家向儿科健康信息系统提供信息的美国儿童医院的数据(该系统是一个临床和资源使用信息数据库),被用于识别2018 - 2024年表明肺炎支原体感染的出院诊断代码。2024年,≤18岁儿童中与肺炎支原体相关的CAP发病率(每1000例住院病例中有12.5例)显著高于2018 - 2023年期间(每1000例住院病例中有2.1例)。在研究期间,11.5%的儿科CAP住院病例列出了肺炎支原体诊断代码,在2024年7月达到峰值53.8%。在儿科肺炎支原体CAP病例中,最高比例出现在6至12岁儿童中(42.6%),其次是2至5岁儿童(25.7%)和13至18岁儿童(21.1%)。最低比例出现在12至23个月龄儿童中(6.4%)和0至11个月龄儿童中(4.2%)。根据住院时间和入住重症监护病房患者的百分比评估,2024年的肺炎支原体感染并不比2018 - 2023年的感染更严重。2024年美国肺炎支原体感染的增加可能高于以往的周期性增加,因为在新冠疫情期间及之后立即持续低发病率之后,易感人群更大。医疗保健提供者应了解肺炎支原体CAP的周期性,并考虑对所有年龄段儿童的呼吸道疾病进行该病原体检测。